CSV February 23, 2023 through February 23, 2025 All Errata for USP–NF How to use

×

**How to Use**

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| ZANAMIVIR | IM | *USP37–NF32* | 5197 | 21-Nov-2014 | 1-Dec-2014 | *USP39–NF34* | *Second* | Line 1 of |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | PURITIES/*Organic Impurities/ Chromatographic system* | | | | | | *Supplement to USP38–NF33* | *Column*: Change 5-?m packing L##[1] to: 5-?m packing L82 |
| CHLORPHENIRAMINE MALEATE | SPECIFIC TESTS/*Optical Rotation, Specific Rotation <781>* | *First Supplement to USP37–NF32* | 6617 | 21-Nov-2014 | 1-Dec-2014 | *USP39–NF34* | *Second Supplement to USP38–NF33* | Line 1 of *Sample*: Change 100 mg/mL in water to: 100 mg/mL in water at 20° |
| HYDROXYPROPYL CELLULOSE | ASSAY | *Second Supplement to USP37–NF32* | 7080 | 21-Nov-2014 | 1-Dec-2014 | *USP39–NF34* | *Second Supplement to USP38–NF33* | Line 1 of *Internal standard solution*: Change Methycyclohexane to: Methylcyclohexane |
| CEFADROXIL FOR ORAL SUSPENSION | IDENTIFICATION/*Thin-Layer C* / | *USP37–NF32* | 2182 | 21-Nov-2014 | 1-Dec-2014 | *USP39–NF34* | *Second Supplement to USP38–NF33* | Line 2 of *Developing solvent system*: Change (60:40:15) to: |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | *Chromatographic system* | | | | | | | (60: 40: 1.5) |
| GANODERMA LUCIDUM FRUITING BODY | SPECIFIC TESTS/ *Botanical Characteristics* | *Revision Bulletin (Official August 01, 2014)* | Online | 21-Nov-2014 | 1-Dec-2014 | *USP39–NF34* | *Second Supplement to USP38–NF33* | Line 6 of *Macroscopic*: Change concentrically culcate to: concentrically sulcate |
| LAMIVUDINE AND ZIDOVUDINE TABLETS | IM PURITIES/*Organic Impurities* | *USP37–NF32* | 3484 | 21-Nov-2014 | 1-Dec-2014 | *USP39–NF34* | *Second Supplement to USP38–NF33* | Row 17 of Column 1 of *Table 2*: Change (the limit includes individual unidentified impurities) to: (the limit includes individual unspecified impurities) |
| WHITE PETROLATUM | IM PURITIES/*Organic Impurities*/*Procedure: Organic Acids* | *USP37–NF32* | 4254 | 21-Nov-2014 | 1-Dec-2014 | *USP39–NF34* | *Second Supplement to USP38–NF33* | Line 1 of *Sample solution*: Change 20.0 g in 100 mL of |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | neutralized alcohol and water (1:2). to: 20.0 g of White Petrolatum in 100 mL of a 1 in 2 mixture of neutralized alcohol and water. |
| SULFAMETHOXAZOLE AND TRIMETHOPRIM TABLETS | ASSAY/*Procedure* | *USP37–NF32* | 4787 | 21-Nov-2014 | 1-Dec-2014 | *USP39–NF34* | *Second Supplement to USP38–NF33* | Line 3 of *Standard solution*: Change in *Mobile phase* from *Sample stock solution* to: in *Mobile phase* from *Standard stock solution* |
| TRIBASIC CALCIUM PHOSPHATE | IMPURITIES/*Dibasic Salt and Calcium Oxide* | *USP37–NF32* | 5883 | 21-Nov-2014 | 1-Dec-2014 | *USP39–NF34* | *Second Supplement to USP38–NF33* | Delete the subsection *Blank*: 25.0 mL of *Titrant* |
| TRAZODONE HYDROCHLORIDE | ADDITIONAL REQUIREMENTS/*USP* | *First Supplement to USP37–NF32* | 6708 | 21-Nov-2014 | 1-Dec-2014 | *USP39–NF34* | *Second Supplement to USP38–NF33* | Line 2 of USP Trazodone Related |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | *Reference Standards <11>* | | | | | | | Compound D RS: Change (2-{3-[4-(4-Bromophenyl)piperazin-1-yl]propyl}-[1 *?* ]pyridin-3(2*H*)-one hydrochloride. to: 2-{3-[4-(3-Bromophenyl)piperazin-1-yl]propyl}-[1 *?* ]pyridin-3(2*H*)-one hydrochloride. |
| PACKAGING AND STORAGE REQUIREMENTS | GENERAL DEFINITIONS | *USP37–NF32* | 315 | 21-Nov-2014 | 1-Dec-2014 | *USP39–NF34* | *Second Supplement to USP38–NF33* | Line 1 of *Single-Dose* (see also *Injections <1>*, *Containers for Injections*): Change A single-unit package for an |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | article intended for parenteral administration. Examples of single-dose containers include prefilled syringes, cartridges, fusion-sealed containers, and closure-sealed containers when so labeled. to: A single-unit package for an article intended for parenteral administration. A single-dose container is labeled as such. Examples of single-dose containers include prefilled syringes, cartridges, fusion-sealed |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | containers, and closure-sealed containers when so labeled. |
| SODIUM PICOSULFATE | CHEMICAL INFORMATION | *Second Supplement to USP37–NF32* | 7253 | 21-Nov-2014 | 1-Dec-2014 | *USP39–NF34* | *Second Supplement to USP38–NF33* | Line 5: Change Disodium 4,4?-(pyridin-2-ylmethanediyl)dibenzenesulfonate to: Disodium 4,4?-(pyridin-2-ylmethanediyl)dibenzenesulfate |
| FLUDARABINE PHOSPHATE | IM PURITIES/*Limit of Sodium* | *USP37–NF32* | 3003 | 21-Nov-2014 | 1-Dec-2014 | *USP39–NF34* | *Second Supplement to USP38–NF33* | Line 1 of *Standard solution*: Change 1 µg/mL of sodium chloride in water to: 1 µg/mL of sodium in water |
| NIFEDIPINE EXTENDED-RELEASE TABLETS | PERFORMANCE TESTS/ *Dissolution <711>/Test 2* | *Second Supplement to USP37–NF32* | Online | 21-Nov-2014 | 1-Dec-2014 | *USP38–NF33* | *USP38–NF33* | Line 1 of *Solution A*: Change sodium phosphate to: |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | dibasic sodium phosphate |
| MINOCYCLINE IMPURITIES FOR INJECTION | | *USP37–NF32* | 3843 | 21-Nov-2014 | 1-Dec-2014 | *USP39–NF34* | *Second Supplement to USP38–NF33* | Line 6 of *Limit of Epiminocycline*: Change [Note—The relative retention times for epiminocycline and minocycline are 0.86 and 1.0, respectively.] to: [Note—The relative retention times for epiminocycline and minocycline are 0.7 and 1.0, respectively.] |
| SULFAMETHO XAZOLE AND TRIMETHOPRIM INJECTION | ASSAY/ *Procedure* | *USP37–NF32* | 4784 | 21-Nov-2014 | 1-Dec-2014 | *USP39–NF34* | *Second Supplement to USP38–NF33* | Line 3 of *Standard solution*: Change in *Mobile phase* from *Sample stock solution* |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | to: in *Mobile phase* from *Standard stock solution* |
| SAW PALMETTO EXTRACT | COMPOSITION /*Content of Long-Chain Alcohols and Sterols* | *USP37–NF32* | 5545 | 21-Nov-2014 | 1-Dec-2014 | *USP39–NF34* | *Second Supplement to USP38–NF33* | Line 3 of *Acceptance criteria*:Add The lipophilic Extract contains 0.15%–0.35% of long-chain alcohols, and the hydroalcoholic Extract contains 0.01%–0.15% of long-chain alcohols on the anhydrous basis. |
| ERYTHROMYCIN DELAYED-RELEASE TABLETS | PERFORMANCE TESTS/ *Dissolution <711>/Test 1/Buffer stage* | *First Supplement to USP37–NF32* | 6633 | 21-Nov-2014 | 1-Dec-2014 | *USP39–NF34* | *Second Supplement to USP38–NF33* | Line 1 of *Standard solution*: Change 0.28 mg/mL of USP Erythromycin RS in *Medium* to: Dissolve USP |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| POLYSORBAT | SPECIFIC | *Second* | 7089 | 21-Nov-2014 | 1-Dec-2014 | *USP39–NF34* | *Second* | Erythromycin RS in *Medium* to obtain a concentration similar to that of the *Sample solution*.<br>AND<br>Line 1 of *Sample solution*:<br>Change<br>Pass portions of the solution under test through a suitable filter.<br>to:<br>If necessary, dilute a filtered portion of the solution under test with *Medium* to obtain a solution containing about 0.28 mg/mL of erythromycin.<br>Line 1 of |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| E 80 | TESTS/*Fats and Fixed Oils, Acid Value <401>* | *Supplement to USP37–NF32* | | | | | *Supplement to USP38–NF33* | *Analysis*: Change with 0.1 N potassium hydroxide or 0.1 N sodium hydroxide to: with 0.1 N potassium hydroxide VS or 0.1 N sodium hydroxide VS |
| ESCITALOPRAM ORAL SOLUTION | IMPURITIES/*Organic Impurities* | *USP37–NF32* | 2580 | 26-Sep-2014 | 1-Oct-2014 | *USP39–NF34* | *First Supplement to USP38–NF33* | Row 6 of Column 1 of *Table 3*: Change Desfluorocitalopram[f] to: Desfluorocitalopram[f,c] |
| KETOPROFEN EXTENDED-RELEASE CAPSULES | PERFORMANCE TESTS/ *Uniformity of Dosage Units <905>*/*System suitability*/*Suitability requirements* | *USP37–NF32* | 3469 | 26-Sep-2014 | 1-Oct-2014 | *USP39–NF34* | *First Supplement to USP38–NF33* | Line 1 of *Tailing factor*: Change NLT 1.5 to: NMT 1.5 |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| STERILE WATER FOR INHALATION | CHEMICAL INFORMATION | *USP37–NF32* | 5174 | 26-Sep-2014 | 1-Oct-2014 | *USP39–NF34* | *First Supplement to USP38–NF33* | Add the chemical formula and molecular weight: $H_2O$ 18.02 |
| STERILE WATER FOR IRRIGATION | ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>* | *USP37–NF32* | 5175 | 26-Sep-2014 | 1-Oct-2014 | *USP39–NF34* | *First Supplement to USP38–NF33* | Add: USP 1,4-Benzoquinone RS AND USP Sucrose RS |
| ETHYLCELLULOSE DISPERSION TYPE B | ASSAY/*Procedure* | *USP37–NF32* | 5981 | 26-Sep-2014 | 1-Oct-2014 | *USP39–NF34* | *First Supplement to USP38–NF33* | Line 3 of *Analysis*: Change Calculate the percentage of ethylcellulose in the portion of Ethylcellulose Dispersion Type B taken: to: Calculate the percentage of the labeled amount of ethylcellulose in the portion of Ethylcellulose Dispersion Type |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| CALCIUM GLUCONATE INJECTION | *Identification* | *USP37–NF32* | 2089 | 26-Sep-2014 | 1-Oct-2014 | *USP39–NF34* | *First Supplement to USP38–NF33* | B taken:<br>Line 1 of *Identification* test *A*: Change<br>A volume of Injection diluted, if necessary, with water to obtain a test solution of calcium gluconate (1 in 100) responds to Identification test *B* under *Calcium Gluconate*.<br>to:<br>Dissolve a quantity of it in water to obtain a test solution containing 10 mg per mL, heating in a water bath at 60° if necessary. Similarly, prepare a Standard |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | solution of USP Potassium Gluconate RS in water containing 10 mg per mL. Apply separate 5-µL portions of the test solution and the Standard solution to a suitable thin-layer chromatographic plate (see *Chromatography <621>*) coated with a 0.25-mm layer of chromatographic silica gel, and allow to dry.Develop the chromatogram in a solvent system consisting of a mixture of alcohol, water, ammonium hydroxide, and |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | ethyl acetate (50: 30: 10: 10) until the solvent front has moved about three-fourths of the length of the plate. Remove the plate from the chamber, and dry at 110° for 20 minutes. Allow to cool, spray with a spray reagent prepared as follows. Dissolve 2.5 g of ammonium molybdate in about 50 mL of 2 N sulfuric acid in a 100-mL volumetric flask, add 1.0 g of ceric sulfate, swirl to dissolve, dilute with 2 N sulfuric acid to volume, and mix. Heat |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | the plate at 110° for about 10 minutes: the principal spot obtained from the test solution corresponds in color, size, and $R_F$ value to that obtained from the Standard solution. |
| IRINOTECAN HYDROCHLORIDE INJECTION | IMPURITIES/*Organic Impurities* | *USP37–NF32* | 3403 | 26-Sep-2014 | 1-Oct-2014 | *USP39–NF34* | *First Supplement to USP38–NF33* | Row 3 of Column 1 of *Table 2*: Change Camptothecin[b] to: Camptothecin[b,d] AND Row 5 of Column 1: Change 7-Ethylcamptothecin[c] to: 7-Ethylcamptothecin[c,d] AND Add a footnote: |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | [d]These process impuritiesare included in the table for identification only and are not included in the *Total impurities*. |
| WATER FOR HEMODIALYSIS | CHEMICAL INFORMATION | *USP37–NF32* | 5173 | 26-Sep-2014 | 1-Oct-2014 | *USP39–NF34* | *First Supplement to USP38–NF33* | Add the chemical formula and molecular weight: $H_2O$ 18.02 |
| STERILE WATER FOR INJECTION | ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>* | *USP37–NF32* | 5175 | 26-Sep-2014 | 1-Oct-2014 | *USP39–NF34* | *First Supplement to USP38–NF33* | Add: USP 1,4-Benzoquinone RS AND USP Sucrose RS |
| CELLACEFATE | ASSAY/*Content of Acetyl* | *USP37–NF32* | 5919 | 26-Sep-2014 | 1-Oct-2014 | *USP39–NF34* | *First Supplement to USP38–NF33* | Line 12 of *Analysis*: Result = {[(*P* ? 0.5182 × *B* )/(100 ? *B*)] ? (0.5772 × *C*)} × 100 to: Result = 100 × [*P* ? (0.5182 × *B*)]/(100 ? *B*) ? |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | (0.5772 × *C*) |
| DACARBAZINE FOR INJECTION | IMPURITIES/*Limit of 2-Azahypoxanthine* | *Second Supplement to USP37–NF32* | Online | 26-Sep-2014 | 1-Oct-2014 | *USP39–NF34* | *First Supplement to USP38–NF33* | Line 2 of *Analysis*: Change 2-azahypoxanthine monohydrate to: 2-azahypoxanthine |
| DIDANOSINE DELAYED-RELEASE CAPSULES | PERFORMANCE TESTS/*Dissolution <711>/Analysis* | *USP37–NF32* | 2603 | 26-Sep-2014 | 1-Oct-2014 | *USP39–NF34* | *First Supplement to USP38–NF33* | Line 11 of the variable definition list: Change $C_S$ = concentration of didanosine in the *Standard solution* (mg/mL) to: $C_S$ = concentration of USP Didanosine Related Compound A RS in the *Standard solution* for the *Acid stage* or |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | concentration of USP Didanosine RS in the *Standard solution* for the *Buffer stage* (mg/mL) |
| OXYBUTYNIN CHLORIDE | SPECIFIC TESTS/*Loss on Drying <731>* | *USP37–NF32* | 4129 | 26-Sep-2014 | 1-Oct-2014 | *USP39–NF34* | *First Supplement to USP38–NF33* | Line 1 of *Acceptance criteria*: Change NMT 3.0% to: NMT 3% |
| STERILE WATER FOR INHALATION | ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>* | *USP37–NF32* | 5174 | 26-Sep-2014 | 1-Oct-2014 | *USP39–NF34* | *First Supplement to USP38–NF33* | Add: USP 1,4-Benzoquinone RS AND USP Sucrose RS |
| PURE STEAM | CHEMICAL INFORMATION | *USP37–NF32* | 5176 | 26-Sep-2014 | 1-Oct-2014 | *USP39–NF34* | *First Supplement to USP38–NF33* | Add the chemical formula and molecular weight: $H_2O$ 18.02 |
| CHLORPHENIRAMINE MALEATE | IMPURITIES/*Organic Impurities* | *First Supplement to USP37–NF32* | 6617 | 26-Sep-2014 | 1-Oct-2014 | *USP39–NF34* | *First Supplement to USP38–NF33* | Line 1 of *Standard solution*: Change 1.1 ?g/mL of |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| DACARBAZINE | *USP Reference standards <11>* | *USP37–NF32* | 2504 | 26-Sep-2014 | 1-Oct-2014 | *USP39–NF34* | *First Supplement to USP38–NF33* | USP Chlorpheniramine Maleate RS in *Diluent*, to: 1.4 ?g/mL of USP Chlorpheniramine Maleate RS in *Diluent*, Line 3 of USP Dacarbazine Related Compound B RS: Change $C_4H_3N_5O$ 137.10 to: $C_4H_3N_5O \cdot H_2O$ 155.12 |
| KETOPROFEN EXTENDED-RELEASE CAPSULES | ASSAY/*Procedure*/*System suitability*/*Suitability requirements* | *USP37–NF32* | 3469 | 26-Sep-2014 | 1-Oct-2014 | *USP39–NF34* | *First Supplement to USP38–NF33* | Line 1 of *Tailing factor*: Change NLT 1.5 to: NMT 1.5 |
| WATER FOR INJECTION | CHEMICAL INFORMATION | *USP37–NF32* | 5173 | 26-Sep-2014 | 1-Oct-2014 | *USP39–NF34* | *First Supplement to USP38–NF33* | Add the chemical formula and molecular weight: $H_2O$ 18.02 |
| STERILE | CHEMICAL | *USP37–NF32* | 5175 | 26-Sep-2014 | 1-Oct-2014 | *USP39–NF34* | *First* | Add the |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| WATER FOR IRRIGATION | INFORMATION | | | | | | *Supplement to USP38–NF33* | chemical formula and molecular weight: $H_2O$ 18.02 |
| POWDERED CELLULOSE | IDENTIFICATION/*B. Procedure* | *USP37–NF32* | 5923 | 26-Sep-2014 | 1-Oct-2014 | *USP39–NF34* | *First Supplement to USP38–NF33* | Fourth equation in *Analysis*: Change Result = 95 × $[?]_c/W_S$ × [(100 ? %LOD)/100] to: Result = [95 × $[?]_c$]/{$W_S$ × [(100 ? %LOD)/100]} |
| BETAMETHASONE SODIUM PHOSPHATE | IM PURITIES/*Limit of Free Betamethasone* | *USP37–NF32* | 1965 | 26-Sep-2014 | 1-Oct-2014 | *USP39–NF34* | *First Supplement to USP38–NF33* | Line 1 of *Sample stock solution*: Change 1.0 mg/mL of Betamethasone Sodium Phosphate in water to: 1.0 mg/mL of Betamethasone Sodium Phosphate in water, prepared as follows. |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | Dissolve 25.0 mg of Betamethasone Sodium Phosphate in water to make 25.0 mL. |
| DROSPIRENONE AND ETHINYL ESTRADIOL TABLETS | IMPURITIES/*Organic Impurities/ Chromatographic system* | *USP37–NF32* | 2739 | 26-Sep-2014 | 1-Oct-2014 | *USP39–NF34* | *First Supplement to USP38–NF33* | Line 2 of *Detector 2*: Change Monitor the signal at 344 nm between 37 and 42 min. to: Monitor the signal at 344 nm for ethinyl estradiol related compound B (typically between 37 and 42 min). |
| PSEUDOEPHEDRINE HYDROCHLORIDE | ASSAY/ *Procedure* | *USP37–NF32* | 4481 | 26-Sep-2014 | 1-Oct-2014 | *USP39–NF34* | *First Supplement to USP38–NF33* | Line 2 of *System suitability solution*: Change 0.02 mg/mL of USP Ephedrine Sulfate RS |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | to:<br>0.002 mg/mL of USP Ephedrine Sulfate RS |
| STERILE WATER FOR INJECTION | CHEMICAL INFORMATION | *USP37–NF32* | 5175 | 26-Sep-2014 | 1-Oct-2014 | *USP39–NF34* | *First Supplement to USP38–NF33* | Add the chemical formula and molecular weight:<br>$H_2O$ 18.02 |
| STERILE PURIFIED WATER | ADDITIONAL REQUIREMENTS | *USP37–NF32* | 5176 | 26-Sep-2014 | 1-Oct-2014 | *USP39–NF34* | *First Supplement to USP38–NF33* | Add a section:<br>*USP Reference Standards <11>*<br>USP 1,4-Benzoquinone RS<br>USP Sucrose RS |
| DEXCHLORPHENIRAMINE MALEATE | IMPURITIES/*Organic Impurities* | *First Supplement to USP37–NF32* | 6626 | 26-Sep-2014 | 1-Oct-2014 | *USP39–NF34* | *First Supplement to USP38–NF33* | Line 1 of *Standard solution*:<br>2.2 ?g/mL of USP Dexchlorpheniramine Maleate RS in *Diluent*,<br>to:<br>2.8 ?g/mL of USP Dexchlorpheniramine Maleate RS in *Diluent*, |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| AMIFOSTINE | ASSAY/*Procedure*/*System suitability*/*Suitability requirements* | *USP37–NF32* | 1717 | 25-Jul-2014 | 1-Aug-2014 | *USP39–NF34* | *First Supplement to USP38–NF33* | Line 1 of *Column efficiency*: Change NLT 100 to: NLT 1000 |
| TIZANIDINE TABLETS | ASSAY/*Procedure*/*System suitability* | *Second Supplement to USP37–NF32* | Online | 25-Jul-2014 | 1-Aug-2014 | *USP39–NF34* | *First Supplement to USP38–NF33* | Change *Sample*: *Standard solution* to: *Samples*: *System suitability solution* and *Standard solution* AND Change *Resolution*: NLT 4.0 between tizanidine and tizanidine related compound C; NLT 4.0 between tizanidine and tizanidine related |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | compound B *Tailing factor*: NMT 2.0 *Relative standard deviation*: NMT 2.0% to: *Resolution*: NLT 4.0 between tizanidine and tizanidine related compound C; NLT 4.0 between tizanidine and tizanidine related compound B, *System suitability solution* *Tailing factor*: NMT 2.0, *Standard solution* *Relative standard deviation*: NMT 2.0%, *Standard* |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | *solution* |
| CEFUROXIME FOR INJECTION | *Constituted solution* | *USP37–NF32* | 2246 | 25-Jul-2014 | 1-Aug-2014 | *USP39–NF34* | *First Supplement to USP38–NF33* | Line 3: Change meets the requirements for *Constituted Solutions* under *Labeling* under *Injections <1>*. to: meets the requirements for *Constituted Solutions* under *Injections <1>*. |
| DULOXETINE DELAYED-RELEASE CAPSULES | IDENTIFICATION | *USP37–NF32* | 2743 | 25-Jul-2014 | 1-Aug-2014 | *USP39–NF34* | *First Supplement to USP38–NF33* | Change *A. Infrared Absorption <197S>* to: *A. Infrared Absorption <197F>* |

**Pagination**


- First page « First
- Previous page ‹ Previous
- …
- Page 27
- Page 28
- Page 29

- Page 30
- Page 31
- Page 32
- Page 33
- Page 34
- Page 35
- …
- Next page Next ›
- Last page Last »